The NCCN Clinical Practice Guidelines in Oncology recommend testing for seven key biomarkers, including KRAS, NRAS, BRAF, and MSI status, to guide personalized treatment strategies and optimize clinical decision-making in CRC [35]. This evidence concerns the gene BRAF and colorectal carcinoma.